{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T14:48:53Z","timestamp":1648565333876},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1177\/2168479014558276","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T10:48:29Z","timestamp":1418986109000},"page":"269-278","update-policy":"http:\/\/dx.doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global Regulatory Dissonance: A Case Study of Industry Views on the Development of Drugs for Postmenopausal Osteoporosis"],"prefix":"10.1007","volume":"49","author":[{"given":"Neal E.","family":"Storm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances J.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"key":"49020269_CR1","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMsa1007467","volume":"363","author":"MA Hamburg","year":"2010","unstructured":"Hamburg MA. Innovation, regulation, and the FDA. N Engl J Med. 2010;363:2228\u20132232.","journal-title":"N Engl J Med"},{"key":"49020269_CR2","volume-title":"Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis","author":"FDA.","year":"1994","unstructured":"FDA. Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Draft. Bethesda, Maryland: Division of Metabolism and Endocrine Drug Products, FDA; 1994."},{"key":"49020269_CR3","volume-title":"Guideline on the Evaluation of New Medicinal Products in the Treatment of Primary Osteoporosis","author":"EMA.","year":"2006","unstructured":"EMA. Guideline on the Evaluation of New Medicinal Products in the Treatment of Primary Osteoporosis. CPMP\/EWP\/552\/95 Rev 2. London: EMA; 2006."},{"key":"49020269_CR4","volume-title":"Considerations for Clinical Trials Evaluating the Treatment of Postmenopausal Women With Osteoporosis Drugs","author":"Chinese FoodDrug Administration.","year":"2011","unstructured":"Chinese Food and Drug Administration. Considerations for Clinical Trials Evaluating the Treatment of Postmenopausal Women With Osteoporosis Drugs. Beijing ICP 09013725. Beijing: Center for Drug Evaluation, Chinese Food and Drug Administration; 2011."},{"key":"49020269_CR5","volume-title":"Guidelines for Clinical Evaluation Methods of Drugs for Osteoporosis","author":"PharmaceuticalMedical Safety Bureau.","year":"1999","unstructured":"Pharmaceutical and Medical Safety Bureau. Guidelines for Clinical Evaluation Methods of Drugs for Osteoporosis. PMSB\/ELD No. 742. Tokyo: Evaluation and Medical Safety Bureau, Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare; 1999."},{"key":"49020269_CR6","volume-title":"Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis","author":"World Health Organization.","year":"1998","unstructured":"World Health Organization. Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Geneva: World Health Organization; 1998."},{"key":"49020269_CR7","volume-title":"prescribing information","author":"Forteo [","year":"2012","unstructured":"Forteo [prescribing information]. Indianapolis, Indiana: Eli Lilly and Co; 2012."},{"issue":"2","key":"49020269_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/0092861512436583","volume":"45","author":"M Solberg","year":"2012","unstructured":"Solberg M, Richmond FJ. Transparency in drug submission processes of 3 Asian countries: a survey of industry views. Drug Inf J. 2012;45 (2):216\u2013225.","journal-title":"Drug Inf J"},{"key":"49020269_CR9","volume-title":"General Principles: EMEA-FDA Parallel Scientific Advice","author":"EMEA-FDA.","year":"2009","unstructured":"EMEA-FDA. General Principles: EMEA-FDA Parallel Scientific Advice. EMEA\/24517\/2009. London: EMEA-FDA; 2009."},{"key":"49020269_CR10","volume-title":"Scrip Regulatory Affairs","author":"S Walker","year":"2011","unstructured":"Walker S, McAuslane N, Liberti L. Developing a common benefit-risk assessment methodology for medicines: a progress report. Scrip Regulatory Affairs. 2011."},{"issue":"1","key":"49020269_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1359\/jbmr.070905","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Cummings SR, Watts NB, et al. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res. 2008;23 (1):159\u2013165.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"49020269_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1359\/jbmr.2003.18.6.1125","volume":"18","author":"EG Colman","year":"2003","unstructured":"Colman EG. The Food and Drug Administration\u2019s osteoporosis guidance document: past, present, and future. J Bone Miner Res. 2003;18 (6):1125\u20131128.","journal-title":"J Bone Miner Res"},{"issue":"22","key":"49020269_CR13","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis: where do we go from here? N Engl J Med. 2012;366 (22):2048\u20132051.","journal-title":"N Engl J Med"},{"key":"49020269_CR14","volume-title":"Recommendation on the Governance of Clinical Trials","author":"OECD.","year":"2013","unstructured":"OECD. Recommendation on the Governance of Clinical Trials. Paris: OECD; 2013."},{"key":"49020269_CR15","unstructured":"Jenkins J. New Drug Approvals: A Status Report. FDA\/CMS Summit. Washington, DC. December 3, 2009."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479014558276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2168479014558276","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1177\/2168479014558276\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2168479014558276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479014558276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T12:44:28Z","timestamp":1598013868000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1177\/2168479014558276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["49020269"],"URL":"https:\/\/doi.org\/10.1177\/2168479014558276","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}